EP4340847A4 - Composition of mesalazine enteric tablet formulation - Google Patents

Composition of mesalazine enteric tablet formulation

Info

Publication number
EP4340847A4
EP4340847A4 EP21940969.5A EP21940969A EP4340847A4 EP 4340847 A4 EP4340847 A4 EP 4340847A4 EP 21940969 A EP21940969 A EP 21940969A EP 4340847 A4 EP4340847 A4 EP 4340847A4
Authority
EP
European Patent Office
Prior art keywords
composition
tablet formulation
enteric tablet
mesalazine enteric
mesalazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21940969.5A
Other languages
German (de)
French (fr)
Other versions
EP4340847A1 (en
Inventor
Hatice Oncel
Onur Pinarbasli
Feristah Bilgin
Hande Gayretli
Nurdan Atilgan
Doganay Asuman Aybey
Nagehan Sarracoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilko Ilac Sanayi ve Ticaret AS
Original Assignee
Ilko Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilko Ilac Sanayi ve Ticaret AS filed Critical Ilko Ilac Sanayi ve Ticaret AS
Publication of EP4340847A1 publication Critical patent/EP4340847A1/en
Publication of EP4340847A4 publication Critical patent/EP4340847A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
EP21940969.5A 2021-05-21 2021-05-21 Composition of mesalazine enteric tablet formulation Pending EP4340847A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2021/050472 WO2022245307A1 (en) 2021-05-21 2021-05-21 Composition of mesalazine enteric tablet formulation

Publications (2)

Publication Number Publication Date
EP4340847A1 EP4340847A1 (en) 2024-03-27
EP4340847A4 true EP4340847A4 (en) 2024-07-17

Family

ID=84141571

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21940969.5A Pending EP4340847A4 (en) 2021-05-21 2021-05-21 Composition of mesalazine enteric tablet formulation

Country Status (2)

Country Link
EP (1) EP4340847A4 (en)
WO (1) WO2022245307A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021391823A1 (en) 2020-12-03 2023-06-29 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
JP2024516108A (en) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート Rapid Design, Build, Test, and Learn Techniques for Identifying and Using Nonviral Carriers
CN115957330A (en) * 2022-12-16 2023-04-14 扬子江药业集团有限公司 Enteric-coated layer, preparation method thereof and oral preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187741A1 (en) * 1994-04-22 1995-11-02 Shunsuke Watanabe Colon-specific drug release system
US20120282333A1 (en) * 2009-10-16 2012-11-08 Ranbaxy Laboratories Limited Delayed release pharmaceutical composition of mesalamine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
CN102048707A (en) * 2010-11-29 2011-05-11 黑龙江天宏药业有限公司 Mesalazine enteric-coated tablet and preparation method thereof
JP6294457B2 (en) * 2013-03-15 2018-03-14 ワーナー チルコット カンパニー， エルエルシーＷａｒｎｅｒ Ｃｈｉｌｃｏｔｔ Ｃｏｍｐａｎｙ， Ｌｌｃ Mesalamine pharmaceutical composition comprising multiple dosing elements for reduced delivery variability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187741A1 (en) * 1994-04-22 1995-11-02 Shunsuke Watanabe Colon-specific drug release system
US20120282333A1 (en) * 2009-10-16 2012-11-08 Ranbaxy Laboratories Limited Delayed release pharmaceutical composition of mesalamine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Summary of Product Characteristics (SmPC) for Salofalk 500 mg gastro-resistant tablets", MEDICINES.ORG, 1 January 2018 (2018-01-01), pages 1 - 5, XP055534701, Retrieved from the Internet <URL:https://www.medicines.org.uk/emc/product/5785/smpc/print> [retrieved on 20181214] *
See also references of WO2022245307A1 *

Also Published As

Publication number Publication date
EP4340847A1 (en) 2024-03-27
WO2022245307A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
EP4340847A4 (en) Composition of mesalazine enteric tablet formulation
IL279464A (en) Pharmaceutical formulation of odevixibat
IL292682A (en) Oral formulation of x842
IL304354A (en) Solid tablet dosage form of ridinilazole
EP3532052A4 (en) Design and composition of cell-stabilized pharmaceutical formulations
GB202010230D0 (en) Pharmaceutical formulation
IL304159A (en) Composition of bl-8040
IL297081A (en) Pharmaceutical formulation
EP4062913C0 (en) Solid oral formulation of utidelone
IL253824A0 (en) Pharmaceutical formulations of c1 esterase inhibitor
IL307482B2 (en) Application of hair-coloring compositions
EP4251153A4 (en) Lyophilized formulations of tegavivint
IL271875A (en) Application of totarol and pharmaceutical composition containing totarol
IL265662A (en) Pharmaceutical compositions of 5-ht6 antagonist
HK1244224B (en) Pharmaceutical composition of mek inhibitor and preparation method thereof
EP3466409C0 (en) Self-emulsifying compositions of weakly ionizable or non-ionizable active pharmaceutical ingredients
IL253788A0 (en) Pharmaceutical formulation of racecadotril
IL312073A (en) Pharmaceutical compositions of efruxifermin
IL314824A (en) Combination formulation of cedazuridine
IL310652A (en) Formulations of radiprodil
ZA202205263B (en) Solid pharmaceutical forms of perampanel
ZA202002086B (en) Alcohol-resistant oral pharmaceutical compositions of lorazepam
EP4208468A4 (en) Radiolabeling and formulation for scale up of 64cu-dotatate
IL297080A (en) Pharmaceutical formulation
GB202100526D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231101

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20240618

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/28 20060101ALI20240612BHEP

Ipc: A61K 9/16 20060101ALI20240612BHEP

Ipc: A61P 1/04 20060101ALI20240612BHEP

Ipc: A61J 3/00 20060101ALI20240612BHEP

Ipc: A61K 31/606 20060101AFI20240612BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)